Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
-
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
-
BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
-
– Growth in third quarter Auryxia™ (ferric citrate) product sales driven by increased breadth and depth of prescribers – – Keryx well positioned with strengthened cash position to support Auryxia...
-
BOSTON, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
-
Keryx implements plan to significantly reduce its annual cash operating expenses, beginning in 2016Increased cash position expected to take Auryxia™ (ferric citrate) franchise to cash flow positive ...
-
BOSTON, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that the European Commission has approved Fexeric® (ferric citrate coordination complex)...
-
BOSTON, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease,...
-
Majority of phosphate binder patients today have access to Auryxia™ CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU Enrollment...
-
BOSTON, July 28, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease,...